{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:08:39Z","timestamp":1789006119795,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypertrophic cardiomyopathy (HCM), arrhythmogenic cardiomyopathy (ACM) and dilated cardiomyopathy (DCM) represent the most frequent structural heart disorders. Due to the complexity of their diagnosis and the frequent occurrence of sudden cardiac death as the first manifestation, these diseases impose a relevant socio-economic burden, highlighting the urgent need for novel disease-specific biomarkers. Here, we assess the potential of microRNAs (miRNAs) as non-invasive predictors for HCM, ACM, and DCM. Electronic databases were systematically searched using relevant keywords pertaining to the disorders and miRNAs. To minimize spurious associations, only studies reporting the area under the curve (AUC) and including healthy controls were taken into account, resulting in the selection of 19 papers for further analyses. miR-29a-3p, miR-185-5p, and miR-454-3p were found overexpressed in HCM, ACM, and DCM, respectively, across different studies. Assessment of the correlation between circulating miRNA levels and cardiac features or genetic background failed to detect consistent profiles among different studies. Thus, further investigations employing consistent approaches and larger cohorts are required to validate the clinical utility of circulating miRNAs as non-invasive biomarkers for these structural cardiomyopathies.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Systematic review registration<\/jats:bold>\n                    \u00a0PROSPERO CRD42023330236.\n                  <\/jats:p>","DOI":"10.1186\/s13643-026-03246-2","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T02:15:20Z","timestamp":1782440120000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating microRNA dysregulation in hypertrophic cardiomyopathy, arrhythmogenic cardiomyopathy, and dilated cardiomyopathy: a systematic review"],"prefix":"10.1186","volume":"15","author":[{"given":"Laurens","family":"L\u00e9ger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Ferron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nele S.","family":"Pauwels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franne","family":"Lingier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Rodriguez-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mora","family":"Murri-Pierri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanda","family":"van Hengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4751-1476","authenticated-orcid":false,"given":"Martina","family":"Calore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"issue":"2","key":"3246_CR1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/eurheartj\/ehm342","volume":"29","author":"P Elliott","year":"2008","unstructured":"Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29(2):270\u20136.","journal-title":"Eur Heart J"},{"issue":"13","key":"3246_CR2","first-page":"209","volume":"108","author":"C Prinz","year":"2011","unstructured":"Prinz C, Farr M, Hering D, Horstkotte D, Faber L. The diagnosis and treatment of hypertrophic cardiomyopathy. Dtsch Arztebl Int. 2011;108(13):209\u201315.","journal-title":"Dtsch Arztebl Int"},{"issue":"3","key":"3246_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1136\/hrt.71.3.215","volume":"71","author":"WJ McKenna","year":"1994","unstructured":"McKenna WJ, Thiene G, Nava A, Fontaliran F, Blomstrom-Lundqvist C, Fontaine G, et al. Diagnosis of arrhythmogenic right ventricular dysplasia\/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Brit Heart J. 1994;71(3):215\u20138.","journal-title":"Brit Heart J"},{"issue":"3","key":"3246_CR4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJM198801213180301","volume":"318","author":"G Thiene","year":"1988","unstructured":"Thiene G, Nava A, Corrado D, Rossi L, Pennelli N. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med. 1988;318(3):129\u201333.","journal-title":"N Engl J Med"},{"issue":"7","key":"3246_CR5","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1161\/CIRCRESAHA.117.309345","volume":"121","author":"D Corrado","year":"2017","unstructured":"Corrado D, Basso C, Judge DP. Arrhythmogenic cardiomyopathy. Circ Res. 2017;121(7):784\u2013802.","journal-title":"Circ Res"},{"issue":"15","key":"3246_CR6","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMc1701400","volume":"376","author":"D Corrado","year":"2017","unstructured":"Corrado D, Link MS, Calkins H. Arrhythmogenic right ventricular cardiomyopathy. N Engl J Med. 2017;376(15):1489\u201390.","journal-title":"N Engl J Med"},{"key":"3246_CR7","doi-asserted-by":"crossref","unstructured":"Lannou S, Mansencal N, Couchoud C, Lassalle M, Dubourg O, Stengel B, et al. The public health burden of cardiomyopathies: insights from a nationwide inpatient study. J Clin Med. 2020;9(4):920.","DOI":"10.3390\/jcm9040920"},{"issue":"4","key":"3246_CR8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1373\/clinchem.2009.134155","volume":"56","author":"KG Moons","year":"2010","unstructured":"Moons KG. Criteria for scientific evaluation of novel markers: a perspective. Clin Chem. 2010;56(4):537\u201341.","journal-title":"Clin Chem"},{"key":"3246_CR9","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3389\/fendo.2018.00402","volume":"9","author":"J O'Brien","year":"2018","unstructured":"O\u2019Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA biogenesis mechanisms of actions, and circulation. Front Endocrinol. 2018;9:402.","journal-title":"Front Endocrinol"},{"issue":"10","key":"3246_CR10","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1161\/CIRCRESAHA.108.183087","volume":"103","author":"V Divakaran","year":"2008","unstructured":"Divakaran V, Mann DL. The emerging role of microRNAs in cardiac remodeling and heart failure. Circ Res. 2008;103(10):1072\u201383.","journal-title":"Circ Res"},{"key":"3246_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.tcm.2016.02.004","volume":"26","author":"S Samanta","year":"2016","unstructured":"Samanta S, Balasubramanian S, Rajasingh S, Patel U, Dhanasekaran A, Dawn B, et al. MicroRNA: a new therapeutic strategy for cardiovascular diseases. Trends Cardiovasc Med. 2016;26:407.","journal-title":"Trends Cardiovasc Med"},{"key":"3246_CR12","first-page":"11","volume":"12","author":"M Alcalde","year":"2023","unstructured":"Alcalde M, Toro R, Bonet F, Cordoba-Caballero JC, Mart\u00ednez-Barrios E, Ranea JA, et al. Role of microRNAs in arrhythmogenic cardiomyopathy: translation as biomarkers into clinical practice. Transl Res. 2023;12:11.","journal-title":"Transl Res"},{"key":"3246_CR13","doi-asserted-by":"crossref","unstructured":"Parvan R, Becker V, Hosseinpour M, Moradi Y, Louch WE, Cataliotti A, et al. Prognostic and predictive microRNA panels for heart failure patients with reduced or preserved ejection fraction: a meta-analysis of Kaplan\u2013Meier-based individual patient data. BMC Med. 2025;23:409.","DOI":"10.1186\/s12916-025-04238-0"},{"key":"3246_CR14","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/ejhf.116","volume":"16","author":"AC Morley-Smith","year":"2014","unstructured":"Morley-Smith AC, Mills A, Jacobs S, Meyns B, Rega F, Simon AR, et al. Circulating microRNAs for predicting and monitoring response to mechanical circulatory support from a left ventricular assist device. Eur J Heart Fail. 2014;16:871\u20139.","journal-title":"Eur J Heart Fail"},{"key":"3246_CR15","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1093\/eurjhf\/hft088","volume":"15","author":"R Marfella","year":"2013","unstructured":"Marfella R, Di Filippo C, Potenza N, Sardu C, Rizzo MR, Siniscalchi M, et al. Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs non-responders. Eur J Heart Fail. 2013;15:1277\u201388.","journal-title":"Eur J Heart Fail"},{"key":"3246_CR16","doi-asserted-by":"crossref","unstructured":"Scolari FL, Faganello LS, Garbin HI, Piva e Mattos B, Biolo A. A systematic review of microRNAs in patients with hypertrophic cardiomyopathy. Int J Cardiol. 2021;327:146\u201354.","DOI":"10.1016\/j.ijcard.2020.11.004"},{"issue":"9","key":"3246_CR17","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.3390\/diagnostics11091720","volume":"11","author":"E Chiti","year":"2021","unstructured":"Chiti E, Paolo MD, Turillazzi E, Rocchi A. MicroRNAs in hypertrophic, arrhythmogenic and dilated cardiomyopathy. Diagnostics. 2021;11(9):1720.","journal-title":"Diagnostics"},{"issue":"5","key":"3246_CR18","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v17.i5.106123","volume":"17","author":"M Mylavarapu","year":"2025","unstructured":"Mylavarapu M, Kodali LSM, Vempati R, Nagarajan JS, Vyas A, Desai R. Circulating microRNAs in predicting fibrosis in hypertrophic cardiomyopathy: a systematic review. World J Cardiol. 2025;17(5):106123.","journal-title":"World J Cardiol"},{"key":"3246_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"3246_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/2046-4053-1-2","volume":"1","author":"A Booth","year":"2012","unstructured":"Booth A, Clarke M, Dooley G, Ghersi D, Moher D, Petticrew M, et al. The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. System Rev. 2012;1:2.","journal-title":"System Rev"},{"key":"3246_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","volume":"75","author":"J McGowan","year":"2016","unstructured":"McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40\u20136.","journal-title":"J Clin Epidemiol"},{"key":"3246_CR22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan \u2014 a web and mobile app for systematic reviews. System Rev. 2016;5:210.","journal-title":"System Rev"},{"issue":"8","key":"3246_CR23","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","volume":"155","author":"PF Whiting","year":"2011","unstructured":"Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529\u201336.","journal-title":"Ann Intern Med"},{"key":"3246_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ijcard.2015.05.185","volume":"196","author":"AA Derda","year":"2015","unstructured":"Derda AA, Thum S, Lorenzen JM, Bavendiek U, Heineke J, Keyser B, et al. Blood-based microRNA signatures differentiate various forms of cardiac hypertrophy. Int J Cardiol. 2015;196:115\u201322.","journal-title":"Int J Cardiol"},{"key":"3246_CR25","doi-asserted-by":"crossref","unstructured":"Huang D, Chen Z, Wang J, Chen Y, Liu D, Lin K. MicroRNA-221 is a potential biomarker of myocardial hypertrophy and fibrosis in hypertrophic obstructive cardiomyopathy. Biosci Rep. 2020;40(1):BSR20191234.","DOI":"10.1042\/BSR20191234"},{"key":"3246_CR26","doi-asserted-by":"crossref","unstructured":"Baulina N, Pisklova M, Kiselev I, Chumakova O, Zateyshchikov D, Favorova O. Circulating miR-499a-5p is a potential biomarker of MYH7-associated hypertrophic cardiomyopathy. Int J Mol Sci. 2022;23(7):3791.","DOI":"10.3390\/ijms23073791"},{"issue":"9","key":"3246_CR27","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.jacc.2013.09.041","volume":"63","author":"R Roncarati","year":"2014","unstructured":"Roncarati R, Anselmi CV, Losi MA, Papa L, Cavarretta E, Martins PD, et al. Circulating miR-29a, among other up-regulated MicroRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2014;63(9):920\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"3246_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.435","volume":"11","author":"M Lombardi","year":"2021","unstructured":"Lombardi M, Lazzeroni D, Benedetti G, Bertoli G, Lazarevic D, Riba M, et al. Plasmatic and myocardial microRNA profiles in patients with Hypertrophic Cardiomyopathy. Clin Transl Med. 2021;11(7):e435.","journal-title":"Clin Transl Med"},{"key":"3246_CR29","doi-asserted-by":"crossref","unstructured":"Ntelios D, Efthimiadis G, Zegkos T, Didagelos M, Katopodi T, Meditskou S, et al. Correlation of miR-146a-5p plasma levels and rs2910164 polymorphism with left ventricle outflow tract obstruction in hypertrophic cardiomyopathy. Hellenic J Cardiol: HJC = Hellenike kardiologike epitheorese. 2021;62(5):349\u2013354.","DOI":"10.1016\/j.hjc.2020.04.015"},{"issue":"1","key":"3246_CR30","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s40001-023-01159-7","volume":"28","author":"L Guo","year":"2023","unstructured":"Guo L, Cai Y, Wang B, Zhang F, Zhao H, Liu L, et al. Characterization of the circulating transcriptome expression profile and identification of novel miRNA biomarkers in hypertrophic cardiomyopathy. Eur J Med Res. 2023;28(1):205.","journal-title":"Eur J Med Res"},{"key":"3246_CR31","doi-asserted-by":"crossref","unstructured":"Yamada S, Hsiao YW, Chang SL, Lin YJ, Lo LW, Chung FP, et al. Circulating microRNAs in arrhythmogenic right ventricular cardiomyopathy with ventricular arrhythmia. Europace. 2018;20(Fi1):f37-f45.","DOI":"10.1093\/europace\/eux289"},{"issue":"1","key":"3246_CR32","doi-asserted-by":"publisher","first-page":"4802","DOI":"10.1038\/s41598-017-05001-z","volume":"7","author":"E Sommariva","year":"2017","unstructured":"Sommariva E, D\u2019Alessandra Y, Farina FM, Casella M, Cattaneo F, Catto V, et al. MiR-320a as a potential novel circulating biomarker of arrhythmogenic cardiomyopathy. Sci Rep. 2017;7(1):4802.","journal-title":"Sci Rep"},{"key":"3246_CR33","doi-asserted-by":"crossref","unstructured":"Sacchetto C, Mohseni Z, Colpaert RMW, Vitiello L, Bortoli MD, Vonh\u00f6gen IGC, et al. Circulating mir-185\u20135p as a potential biomarker for arrhythmogenic right ventricular cardiomyopathy. Cells. 2021;10(10):2578.","DOI":"10.3390\/cells10102578"},{"key":"3246_CR34","doi-asserted-by":"crossref","unstructured":"Bueno Marinas M, Celeghin R, Cason M, Thiene G, Basso C, Pilichou K. The role of MicroRNAs in arrhythmogenic cardiomyopathy: biomarkers or innocent bystanders of disease progression? Int J Mol Sci. 2020;21(17):6434.","DOI":"10.3390\/ijms21176434"},{"issue":"1","key":"3246_CR35","doi-asserted-by":"publisher","first-page":"65","DOI":"10.5603\/CJ.a2016.0097","volume":"24","author":"H Wang","year":"2017","unstructured":"Wang H, Chen F, Tong J, Li Y, Cai J, Wang Y, et al. Circulating microRNAs as novel biomarkers for dilated cardiomyopathy. Cardiol J. 2017;24(1):65\u201373.","journal-title":"Cardiol J"},{"key":"3246_CR36","unstructured":"Calderon-Dominguez M, Belmonte T, Ramos M, Quezada-Feijoo M, Perez-Navarro A, Alcala M, et al. Role of circulating microRNA-16\u20135p, a new therapeutic target for ischemic dilated cardiomyopathy. Eur J Cardio Nurs. 2020;19(1_SUPPL):S55-S55."},{"issue":"8","key":"3246_CR37","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00109-018-1666-1","volume":"96","author":"R Toro","year":"2018","unstructured":"Toro R, Blasco-Turrion S, Morales-Ponce FJ, Gonzalez P, Martinez-Camblor P, Lopez-Granados A, et al. Plasma microRNAs as biomarkers for Lamin A\/C-related dilated cardiomyopathy. J Mol Med. 2018;96(8):845\u201356.","journal-title":"J Mol Med"},{"issue":"1","key":"3246_CR38","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/ehf2.13090","volume":"8","author":"G Aleshcheva","year":"2021","unstructured":"Aleshcheva G, Pietsch H, Escher F, Schultheiss HP. MicroRNA profiling as a novel diagnostic tool for identification of patients with inflammatory and\/or virally induced cardiomyopathies. ESC Heart Failure. 2021;8(1):408\u201322.","journal-title":"ESC heart failure"},{"issue":"5","key":"3246_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1258","volume":"13","author":"X Cheng","year":"2023","unstructured":"Cheng X, Jian D, Xing J, Liu C, Liu Y, Cui C, et al. Circulating cardiac MicroRNAs safeguard against dilated cardiomyopathy. Clin Transl Med. 2023;13(5):e1258.","journal-title":"Clin Transl Med"},{"issue":"1","key":"3246_CR40","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ihj.2012.12.022","volume":"65","author":"KL Fan","year":"2013","unstructured":"Fan KL, Zhang HF, Shen J, Zhang Q, Li XL. Circulating microRNAs levels in Chinese heart failure patients caused by dilated cardiomyopathy. Indian Heart J. 2013;65(1):12\u20136.","journal-title":"Indian Heart J"},{"key":"3246_CR41","doi-asserted-by":"crossref","unstructured":"Fayez AG, Esmaiel NN, Salem SM, Ashaat EA, El-Saiedi SA, El Ruby MO. miR-454\u20133p and miR-194\u20135p targeting cardiac sarcolemma ion exchange transcripts are potential noninvasive diagnostic biomarkers for childhood dilated cardiomyopathy in Egyptian patients. Egypt Heart J: (EHJ). 2022;74(1):65.","DOI":"10.1186\/s43044-022-00300-x"},{"issue":"13","key":"3246_CR42","first-page":"982","volume":"35","author":"M Jiao","year":"2020","unstructured":"Jiao M, You H, Wang Z, Gu Y, Wang X, Liang Y, et al. Diagnosis of dilated cardiomyopathy in children based on microRNA sequencing technology. Chin J Appl Clin Pedia. 2020;35(13):982\u20137.","journal-title":"Chin J Appl Clin Pedia"},{"issue":"9862","key":"3246_CR43","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S0140-6736(12)60397-3","volume":"381","author":"BJ Maron","year":"2013","unstructured":"Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet (London, England). 2013;381(9862):242\u201355.","journal-title":"Lancet (London, England)"},{"issue":"2","key":"3246_CR44","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.hlc.2021.04.019","volume":"31","author":"MR Sons\u00f6z","year":"2022","unstructured":"Sons\u00f6z MR, Yilmaz M, Cevik E, Orta H, Bilge AK, Elitok A, et al. Circulating levels of MicroRNAs in hypertrophic cardiomyopathy: the relationship with left ventricular hypertrophy, left atrial dilatation and ventricular depolarisation-repolarisation parameters. Heart Lung Circ. 2022;31(2):199\u2013206.","journal-title":"Heart Lung Circ"},{"issue":"7","key":"3246_CR45","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","volume":"121","author":"AJ Marian","year":"2017","unstructured":"Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121(7):749\u201370.","journal-title":"Circ Res"},{"issue":"19","key":"3246_CR46","doi-asserted-by":"publisher","first-page":"10574","DOI":"10.3390\/ijms221910574","volume":"22","author":"CH Hsu","year":"2021","unstructured":"Hsu CH, Liu IF, Kuo HF, Li CY, Lian WS, Chang CY, et al. miR-29a-3p\/THBS2 axis regulates PAH-induced cardiac fibrosis. Int J Mol Sci. 2021;22(19):10574.","journal-title":"Int J Mol Sci"},{"key":"3246_CR47","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.yjmcc.2021.12.011","volume":"165","author":"R Lin","year":"2022","unstructured":"Lin R, Rahtu-Korpela L, Szabo Z, Kemppi A, Skarp S, Kiviniemi AM, et al. MiR-185-5p regulates the development of myocardial fibrosis. J Mol Cell Cardiol. 2022;165:130\u201340.","journal-title":"J Mol Cell Cardiol"},{"issue":"6","key":"3246_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2018.e00639","volume":"4","author":"Y Kakimoto","year":"2018","unstructured":"Kakimoto Y, Tanaka M, Hayashi H, Yokoyama K, Osawa M. Overexpression of miR-221 in sudden death with cardiac hypertrophy patients. Heliyon. 2018;4(6):e00639.","journal-title":"Heliyon"},{"issue":"5","key":"3246_CR49","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1159\/000443113","volume":"38","author":"H Zhang","year":"2016","unstructured":"Zhang H, Li S, Zhou Q, Sun Q, Shen S, Zhou Y, et al. Qiliqiangxin attenuates phenylephrine-induced cardiac hypertrophy through downregulation of miR-199a-5p. Cell Physiol Biochem. 2016;38(5):1743\u201351.","journal-title":"Cell Physiol Biochem"},{"issue":"9","key":"3246_CR50","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.18632\/aging.206309","volume":"17","author":"FQ Fenzl","year":"2025","unstructured":"Fenzl FQ, Lederer EM, Brumma L, Kr\u00fcger P, Schroll M, Wilming F, et al. Deregulated miR-145 and miR-27b in Hutchinson-Gilford progeria syndrome: implications for adipogenesis. Aging. 2025;17(9):2278\u2013311.","journal-title":"Aging"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-026-03246-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-026-03246-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-026-03246-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:45:36Z","timestamp":1789004736000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13643-026-03246-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3246"],"URL":"https:\/\/doi.org\/10.1186\/s13643-026-03246-2","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"21 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"249"}}